ARTICLE
22 November 2021

What's The Wait? – Number Of MDR And IVDR Notified Bodies Remains Stubbornly Low

B
Bristows

Contributor

Bristows logo
We are a hub for litigation, transactions and advice. We don’t work to billing targets, ensuring clients gets the right combination of experts. It’s a rare approach defining the quality of our advice. We recruit inquisitive minds, many with science and technology backgrounds. We are Bristows, seeing things differently for those shaping tomorrow.
We have previously written at length about the continuing regulatory bottlenecks caused by the low numbers of notified bodies for the EU's Medical Device Regulation and In Vitro Diagnostic Medical Devices Regulation.
European Union Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

We have previously written at length about the continuing regulatory bottlenecks caused by the low numbers of notified bodies for the EU's Medical Device Regulation (MDR) and In Vitro Diagnostic Medical Devices Regulation (IVDR).

A new set of slides from the European Commission sheds some light on where all the notified bodies have gone.

The good news is that we do have 24 notified bodies for MDR. However, 29 applications for designation under MDR remain in progress. Of these, two notified bodies will be designated imminently (which should bring us to 26 by Christmas 2022). However, ten applicants haven't even received preliminary assessment reports, especially when considering the relative speed and ease of this initial stage.

Some 18 months after the original date of application of the MDR (May 2020), it is disconcerting that this bottleneck remains and is not going to be resolved in the near future.

The situation is similar under the IVDR, prompting the EC to take action to alleviate what they called a "grave shortage" in notified body capacity. With just over six months to go before the date of application, only six notified bodies have been designated and only 17 applications have been received (and four of them have yet to even receive a PAR).

The IVDR poses significant challenges given the up-classification of virtually all products within its scope.

The sector can do little more than cross its fingers and hope that the pending applications proceed more quickly through the process.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

ARTICLE
22 November 2021

What's The Wait? – Number Of MDR And IVDR Notified Bodies Remains Stubbornly Low

European Union Food, Drugs, Healthcare, Life Sciences

Contributor

Bristows logo
We are a hub for litigation, transactions and advice. We don’t work to billing targets, ensuring clients gets the right combination of experts. It’s a rare approach defining the quality of our advice. We recruit inquisitive minds, many with science and technology backgrounds. We are Bristows, seeing things differently for those shaping tomorrow.
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More